FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078443595> ?p ?o ?g. }

• W2078443595 endingPage "552" @default.
• W2078443595 startingPage "542" @default.
• W2078443595 abstract "Metastatic EGFR-mutant lung cancers are sensitive to the first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib, and afatinib, but resistance develops. Acquired resistance to gefitinib or erlotinib occurs most commonly (>50%) via the emergence of a second-site EGFR mutation, T790M. Two strategies to overcome T790M-mediated resistance are dual inhibition of EGFR with afatinib plus the anti-EGFR antibody cetuximab (A+C), or mutant-specific EGFR inhibition with AZD9291. A+C and AZD9291 are now also being tested as first-line therapies, but whether these therapies will extend progression-free survival or induce more aggressive forms of resistance in this setting remains unknown. We modeled resistance to multiple generations of anti-EGFR therapies preclinically to understand the effects of sequential treatment with anti-EGFR agents on drug resistance and determine the optimal order of treatment. Using a panel of erlotinib/afatinib-resistant cells, including a novel patient-derived cell line (VP-2), we found that AZD9291 was more potent than A+C at inhibiting cell growth and EGFR signaling in this setting. Four of four xenograft-derived A+C-resistant cell lines displayed in vitro and in vivo sensitivity to AZD9291, but four of four AZD9291-resistant cell lines demonstrated cross-resistance to A+C. Addition of cetuximab to AZD9291 did not confer additive benefit in any preclinical disease setting. This work, emphasizing a mechanistic understanding of the effects of therapies on tumor evolution, provides a framework for future clinical trials testing different treatment sequences. This paradigm is applicable to other tumor types in which multiple generations of inhibitors are now available." @default.
• W2078443595 created "2016-06-24" @default.
• W2078443595 creator A5004111432 @default.
• W2078443595 creator A5006688612 @default.
• W2078443595 creator A5008171524 @default.
• W2078443595 creator A5014559198 @default.
• W2078443595 creator A5025951912 @default.
• W2078443595 creator A5026352956 @default.
• W2078443595 creator A5029484872 @default.
• W2078443595 creator A5037844360 @default.
• W2078443595 creator A5046345178 @default.
• W2078443595 creator A5047002272 @default.
• W2078443595 creator A5055529171 @default.
• W2078443595 creator A5056121087 @default.
• W2078443595 creator A5056599239 @default.
• W2078443595 creator A5062616992 @default.
• W2078443595 creator A5067248479 @default.
• W2078443595 creator A5074068244 @default.
• W2078443595 creator A5074540558 @default.
• W2078443595 creator A5088553415 @default.
• W2078443595 date "2015-02-01" @default.
• W2078443595 modified "2023-09-22" @default.
• W2078443595 title "Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer" @default.
• W2078443595 cites W1919257374 @default.
• W2078443595 cites W1980497534 @default.
• W2078443595 cites W1983774108 @default.
• W2078443595 cites W1984068087 @default.
• W2078443595 cites W1986525211 @default.
• W2078443595 cites W1988939419 @default.
• W2078443595 cites W1998971866 @default.
• W2078443595 cites W2002937040 @default.
• W2078443595 cites W2003984225 @default.
• W2078443595 cites W2043696829 @default.
• W2078443595 cites W2065141010 @default.
• W2078443595 cites W2080748037 @default.
• W2078443595 cites W2081365151 @default.
• W2078443595 cites W2081801534 @default.
• W2078443595 cites W2088540000 @default.
• W2078443595 cites W2093613683 @default.
• W2078443595 cites W2096198395 @default.
• W2078443595 cites W2096540669 @default.
• W2078443595 cites W2100626226 @default.
• W2078443595 cites W2103441770 @default.
• W2078443595 cites W2111662961 @default.
• W2078443595 cites W2117784514 @default.
• W2078443595 cites W2118604864 @default.
• W2078443595 cites W2119180969 @default.
• W2078443595 cites W2122732537 @default.
• W2078443595 cites W2129360604 @default.
• W2078443595 cites W2129656399 @default.
• W2078443595 cites W2132157071 @default.
• W2078443595 cites W2135550035 @default.
• W2078443595 cites W2138601221 @default.
• W2078443595 cites W2139236349 @default.
• W2078443595 cites W2143913849 @default.
• W2078443595 cites W2145980885 @default.
• W2078443595 cites W2156647409 @default.
• W2078443595 cites W2160982674 @default.
• W2078443595 cites W2161821474 @default.
• W2078443595 cites W2166084034 @default.
• W2078443595 cites W2169460814 @default.
• W2078443595 cites W2461360472 @default.
• W2078443595 cites W2462237620 @default.
• W2078443595 cites W2605292800 @default.
• W2078443595 cites W4247053599 @default.
• W2078443595 doi "https://doi.org/10.1158/1535-7163.mct-14-0723" @default.
• W2078443595 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4338015" @default.
• W2078443595 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25477325" @default.
• W2078443595 hasPublicationYear "2015" @default.
• W2078443595 type Work @default.
• W2078443595 sameAs 2078443595 @default.
• W2078443595 citedByCount "26" @default.
• W2078443595 countsByYear W20784435952015 @default.
• W2078443595 countsByYear W20784435952016 @default.
• W2078443595 countsByYear W20784435952017 @default.
• W2078443595 countsByYear W20784435952018 @default.
• W2078443595 countsByYear W20784435952019 @default.
• W2078443595 countsByYear W20784435952020 @default.
• W2078443595 countsByYear W20784435952022 @default.
• W2078443595 crossrefType "journal-article" @default.
• W2078443595 hasAuthorship W2078443595A5004111432 @default.
• W2078443595 hasAuthorship W2078443595A5006688612 @default.
• W2078443595 hasAuthorship W2078443595A5008171524 @default.
• W2078443595 hasAuthorship W2078443595A5014559198 @default.
• W2078443595 hasAuthorship W2078443595A5025951912 @default.
• W2078443595 hasAuthorship W2078443595A5026352956 @default.
• W2078443595 hasAuthorship W2078443595A5029484872 @default.
• W2078443595 hasAuthorship W2078443595A5037844360 @default.
• W2078443595 hasAuthorship W2078443595A5046345178 @default.
• W2078443595 hasAuthorship W2078443595A5047002272 @default.
• W2078443595 hasAuthorship W2078443595A5055529171 @default.
• W2078443595 hasAuthorship W2078443595A5056121087 @default.
• W2078443595 hasAuthorship W2078443595A5056599239 @default.
• W2078443595 hasAuthorship W2078443595A5062616992 @default.
• W2078443595 hasAuthorship W2078443595A5067248479 @default.
• W2078443595 hasAuthorship W2078443595A5074068244 @default.
• W2078443595 hasAuthorship W2078443595A5074540558 @default.
• W2078443595 hasAuthorship W2078443595A5088553415 @default.

• next